Faron Pharmaceuticals H2 2023: Entering a new phase - Redeye

Redeye provides a research update on Faron Pharmaceuticals following the company’s recent annual report, precarious financial situation, and clinical progress with lead candidate Bexmarilimab. With upcoming BEXMAB read-outs and a planned larger share issue ahead, we abstain from making any changes in our valuation for now.

Länk till analysen i sin helhet: https://www.redeye.se/research/990370/faron-pharmaceuticals-h2-2023-entering-a-new-phase?utm_source=finwire&utm_medium=RSS